½ÃÀ庸°í¼­
»óǰÄÚµå
1595413

Æó·Å °Ë»ç ½ÃÀå : À¯Çü, ¹æ¹ý, ±â¼ú, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Pneumonia Testing Market by Type (Instruments, Reagents & Consumables), Method (Immunodiagnostics, Molecular Diagnostics, Point of Care Testing), Technology, End-user - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Æó·Å °Ë»ç ½ÃÀåÀº 2023³â 14¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 15¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGR 6.23%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 222¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Æó·Å °Ë»ç¿¡´Â ÈäºÎ ¿¢½º·¹ÀÌ¿Í °°Àº ¿µ»ó Áø´Ü ±â¼ú, °´´ã ¹è¾ç°ú °°Àº ÀÓ»ó °Ë»ç, ¹ÚÅ׸®¾Æ ¹× ¹ÙÀÌ·¯½º º´¿øÃ¼¸¦ °ËÃâÇÏ´Â PCR°ú °°Àº ½Å¼Ó ºÐÀÚ ºÐ¼®°ú °°Àº Æó·ÅÀ» ½Äº°ÇÏ´Â µ¥ »ç¿ëµÇ´Â ´Ù¾çÇÑ Áø´Ü ¹æ¹ýÀÌ Æ÷ÇԵ˴ϴÙ. Æó·Å °Ë»çÀÇ Çʿ伺Àº ÀûÀýÇÑ Ä¡·á Àü·«À» ½ÃÀÛÇϰí, °¨¿° È®»êÀ» ¾ïÁ¦Çϰí, ÀÌ È£Èí±â Áúȯ°ú °ü·ÃµÈ »ç¸Á·üÀ» ³·Ãß±â À§ÇØ ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´ÜÀÌ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù. °Ë»ç ¿ëµµ´Â º´¿ø, ¿Ü·¡ Áø·á¼Ò, Áø´Ü ½ÇÇè½ÇÀ̸ç, ÃÖÁ¾ ¿ëµµ´Â ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü, °øÁß º¸°Ç ±â°ü, ¿¬±¸ ±â°ü µîÀÔ´Ï´Ù. Æó·Å °Ë»ç ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â Àü ¼¼°è Æó·Å ¹ßº´·ü Áõ°¡, °¨¿°¼º Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áø´Ü ¹æ¹ýÀÇ ±â¼ú ¹ßÀü, ÀÇ·á Áø´Ü¿¡ ÀΰøÁö´ÉÀÇ ÅëÇÕ µîÀÌ ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­´Â Á¶±â ¹ß°ß°ú ½Ç½Ã°£ ÀÇ»ç°áÁ¤À» °­È­ÇÏ´Â ÇöÀåÁø´Ü(Point-of-Care) °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ Å« ±âȸ·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ±×·¯³ª °í±Þ Áø´Ü µµ±¸ÀÇ ³ôÀº °¡°Ý, ±ÔÁ¦ À庮, °Ë»ç ¹Î°¨µµ ¹× ƯÀ̵µ ÆíÂ÷·Î ÀÎÇÑ À§¾ç¼º °á°úÀÇ °¡´É¼º µîÀÌ ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç×»ýÁ¦ ³»¼º ¹ÚÅ׸®¾ÆÀÇ ÃâÇöÀº Áø´Ü Á¤È®µµ Çâ»ó°ú ½Å¼ÓÇÑ °Ë»ç ±â´ÉÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. Çõ½ÅÀÇ ÃÊÁ¡Àº º´¿øÃ¼ °ËÃâÀ» À§ÇÑ CRISPR ±â¼ú ÅëÇÕ ¹× ¹ÙÀÌ¿À¼¾¼­ ±â¼ú °­È­¿Í °°ÀÌ Á¤È®¼º°ú ÆíÀǼºÀ» °âºñÇÑ ºñ¿ë È¿À²ÀûÀÎ ÈÞ´ë¿ë °Ë»ç ÀåºñÀÇ °³¹ßÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÇÏÀÌÅ×Å© ±â¾÷°ú ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü °£ÀÇ Çù·ÂÀº ´õ ¸¹Àº ÁøÀüÀ» °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. Æó·Å °Ë»ç ½ÃÀåÀº Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å°ú ÇöÀçÀÇ ÇѰ踦 ±Øº¹Çϱâ À§ÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¿¡ µû¶ó ¿ªµ¿ÀûÀ̰í Å« ÆøÀÇ ¼ºÀåÀ» ÀÌ·ê ¼ö ÀÖ´Â ¿©°ÇÀÌ Á¶¼ºµÇ¾î ÀÖ½À´Ï´Ù. Æó·Å Áø´Ü ½ÃÀå¿¡¼­ °æÀï ¿ìÀ§¸¦ À¯ÁöÇÏ°í ½ÃÀå ÁöÀ§¸¦ Çâ»ó½ÃŰ·Á´Â ±â¾÷µéÀº ÀÌ·¯ÇÑ °úÁ¦¸¦ Á¾ÇÕÀûÀ¸·Î ÇØ°áÇÏ°í »õ·Î¿î ±âȸ¸¦ Ȱ¿ëÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 14¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 15¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 22¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 6.23%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Æó·Å °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Æó·Å °Ë»ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è ³ëÀÎ Àα¸ Áõ°¡¿¡ µû¸¥ Æó·Å À¯º´·ü Áõ°¡
    • Æó·Å¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ ÀÇ·á±â°üÀÇ ÀÌ´Ï¼ÅÆ¼ºê Ȱ¿ë °¡´É¼º
    • Æó·Å¿¡ ´ëÇÑ ÇöÀå °Ë»ç(POCT)¿¡ ´ëÇÑ °ü½É Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¾ÇÕÀûÀÎ Æó·Å °Ë»çÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • Æó·Å¿¡ ´ëÇÑ ½Å¼ÓÇϰí Á¤È®ÇÑ °í±Þ Áø´Ü °Ë»ç °³¹ß Áõ°¡
    • Çõ½ÅÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ±â¹ÝÀ¸·Î ÇÑ °Ë»ç °¡´É¼ºÀÇ È®´ë
  • ½ÃÀå °úÁ¦
    • ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­ °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼º Á¦ÇÑ

Portre's Five Forces: Æó·Å °Ë»ç ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Æó·Å °Ë»ç ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Æó·Å °Ë»ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Æó·Å °Ë»ç ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Æó·Å °Ë»ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Æó·Å °Ë»ç ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Æó·Å °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ Æó·Å °Ë»ç ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸®´Ù.

Æó·Å °Ë»ç ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Æó·Å °Ë»ç ½ÃÀå : À¯Çüº°

  • ±â±â
  • ½Ã¾à ¹× ¼Ò¸ðǰ

Á¦7Àå Æó·Å °Ë»ç ½ÃÀå : ¹æ¹ýº°

  • ¸é¿ªÁø´Ü
  • ºÐÀÚÁø´Ü
  • POC(Point of Care) °Ë»ç

Á¦8Àå Æó·Å °Ë»ç ½ÃÀå : ±â¼úº°

  • È¿¼Ò ¸é¿ªÃøÁ¤¹ý
  • ¸é¿ª Çü±¤¹ý
  • ¸é¿ªÁ¶Á÷È­ÇÐ
  • ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ
  • ¿þ½ºÅÏ ºí·Ô

Á¦9Àå Æó·Å °Ë»ç ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Áø´Ü ½ÇÇè½Ç
  • º´¿ø ¹× Ŭ¸®´Ð

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ Æó·Å °Ë»ç ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Æó·Å °Ë»ç ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Æó·Å °Ë»ç ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Curetis GmbH
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Hain Lifescience GmbH by Bruker Corporation
  • Hologic, Inc.
  • Intec Products, Inc.
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • OpGen Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • True Bearing Diagnostics, Inc.
LSH

The Pneumonia Testing Market was valued at USD 1.49 billion in 2023, expected to reach USD 1.58 billion in 2024, and is projected to grow at a CAGR of 6.23%, to USD 2.28 billion by 2030.

Pneumonia testing encompasses various diagnostic methods used to identify pneumonia, including imaging techniques like chest X-rays, laboratory tests like sputum cultures, and rapid molecular assays like PCR to detect bacterial and viral pathogens. The necessity of pneumonia testing is driven by the need for prompt and accurate diagnosis to initiate appropriate treatment strategies, reduce infection spread, and lower mortality rates associated with this respiratory condition. Applications are found across hospitals, outpatient clinics, and diagnostic laboratories, with end-use sectors including healthcare providers, public health organizations, and research institutions. Key growth factors driving the pneumonia testing market include the rising incidence of pneumonia globally, increased awareness about infectious diseases, technological advancements in diagnostic methods, and the integration of artificial intelligence in medical diagnostics. A significant opportunity lies in the expanding demand for point-of-care testing that enhances early detection and real-time decision-making, particularly in resource-constrained settings. However, challenges such as the high cost of advanced diagnostic tools, regulatory hurdles, and the potential for false results due to variability in test sensitivity and specificity can limit market growth. Additionally, emerging antibiotic-resistant strains of bacteria underscore the need for improved diagnostic accuracy and rapid testing capabilities. Innovations may focus on developing cost-effective, portable testing devices that combine high accuracy with simplicity, such as integrating CRISPR technology for pathogen detection or enhancing biosensor technology. Collaborations between tech firms and healthcare providers could unlock further advancements. The market for pneumonia testing is dynamic and poised for substantial growth, contingent on continued technological innovation and strategic initiatives that address current limitations. Comprehensively tackling these challenges and leveraging emerging opportunities will be vital for companies aiming to maintain competitive advantage and enhance market position in pneumonia diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 1.49 billion
Estimated Year [2024] USD 1.58 billion
Forecast Year [2030] USD 2.28 billion
CAGR (%) 6.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pneumonia Testing Market

The Pneumonia Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of pneumonia with expanding geriatric population worldwide
    • Availability of initiatives by healthcare organizations to raise awareness about pneumonia
    • Growing inclination towards point-of-care testing (POCT) for pneumonia
  • Market Restraints
    • High cost of comprehensive pneumonia testing
  • Market Opportunities
    • Increasing development of advanced rapid and accurate diagnostic tests for pneumonia
    • Expanding potential for innovative biomarker-based tests
  • Market Challenges
    • Limited access to testing in resource-limited settings

Porter's Five Forces: A Strategic Tool for Navigating the Pneumonia Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pneumonia Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pneumonia Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pneumonia Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pneumonia Testing Market

A detailed market share analysis in the Pneumonia Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pneumonia Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pneumonia Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pneumonia Testing Market

A strategic analysis of the Pneumonia Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pneumonia Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Curetis GmbH, Danaher Corporation, DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Hain Lifescience GmbH by Bruker Corporation, Hologic, Inc., Intec Products, Inc., Luminex Corporation, Meridian Bioscience, Inc., OpGen Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Quidel Corporation, Sekisui Diagnostics, LLC, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and True Bearing Diagnostics, Inc..

Market Segmentation & Coverage

This research report categorizes the Pneumonia Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Instruments and Reagents & Consumables.
  • Based on Method, market is studied across Immunodiagnostics, Molecular Diagnostics, and Point of Care Testing.
  • Based on Technology, market is studied across Enzyme Linked Immunosorbent Assay, Immunofluorescence, Immunohistochemistry, Polymerase Chain Reaction, and Western Blot.
  • Based on End-user, market is studied across Diagnostic Laboratories and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of pneumonia with expanding geriatric population worldwide
      • 5.1.1.2. Availability of initiatives by healthcare organizations to raise awareness about pneumonia
      • 5.1.1.3. Growing inclination towards point-of-care testing (POCT) for pneumonia
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of comprehensive pneumonia testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing development of advanced rapid and accurate diagnostic tests for pneumonia
      • 5.1.3.2. Expanding potential for innovative biomarker-based tests
    • 5.1.4. Challenges
      • 5.1.4.1. Limited access to testing in resource-limited settings
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pneumonia Testing Market, by Type

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Consumables

7. Pneumonia Testing Market, by Method

  • 7.1. Introduction
  • 7.2. Immunodiagnostics
  • 7.3. Molecular Diagnostics
  • 7.4. Point of Care Testing

8. Pneumonia Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. Enzyme Linked Immunosorbent Assay
  • 8.3. Immunofluorescence
  • 8.4. Immunohistochemistry
  • 8.5. Polymerase Chain Reaction
  • 8.6. Western Blot

9. Pneumonia Testing Market, by End-user

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics

10. Americas Pneumonia Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pneumonia Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pneumonia Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Becton, Dickinson and Company
  • 3. Bio-Rad Laboratories, Inc.
  • 4. bioMerieux SA
  • 5. Curetis GmbH
  • 6. Danaher Corporation
  • 7. DiaSorin S.p.A.
  • 8. Eurofins Scientific SE
  • 9. F. Hoffmann-La Roche Ltd
  • 10. Hain Lifescience GmbH by Bruker Corporation
  • 11. Hologic, Inc.
  • 12. Intec Products, Inc.
  • 13. Luminex Corporation
  • 14. Meridian Bioscience, Inc.
  • 15. OpGen Inc.
  • 16. QIAGEN N.V.
  • 17. Quest Diagnostics Incorporated
  • 18. Quidel Corporation
  • 19. Sekisui Diagnostics, LLC
  • 20. Siemens Healthineers AG
  • 21. Thermo Fisher Scientific Inc.
  • 22. Trinity Biotech PLC
  • 23. True Bearing Diagnostics, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦